| Literature DB >> 29456106 |
Xin He1, Xin-Yang Li1, Jing-Wei Liang1, Chong Cao1, Shuai Li1, Ting-Jian Zhang1, Fan-Hao Meng2.
Abstract
Rucaparib and PJ34 were used as the structural model for the design of novel 5H-dibenzo[b,e]azepine-6,11-dione derivatives containing 1,3,4-oxadiazole units. And target compounds were successfully synthesized through a 3-step synthetic strategy. All target compounds were screened for their anti-proliferative effects against OVCAR-3 cell line. Preliminary biological study of these compounds provided potent compounds d21 and d22 with better activities than Rucaparib.Entities:
Keywords: 5H-dibenzo[b,e]azepine-6,11-dione; Anticancer; PARP-1 inhibitors
Mesh:
Substances:
Year: 2018 PMID: 29456106 DOI: 10.1016/j.bmcl.2018.02.008
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823